Join to access to all OVN content. Join for Free
Season 1, Episode 18: Challenges Facing the Pharma Universe with Jack West

Season 1, Episode 18: Challenges Facing the Pharma Universe with Jack West


Share This Article


In this episode of the Pharmaverse podcast, host Michael Pietrack interviews Jack West, the VP of Clinical Development at Summit Therapeutics. They discuss Jack's transition from being a practicing oncologist to working in the pharmaceutical industry, the importance of collaborations with pharma, and the challenges and rewards of working in a small pharma company. "Going into a pharma company is like riding a mechanical bull. The directions change frequently and sometimes you're not ready for them." Jack also shares his insights on leadership best practices and the top challenges facing the pharma industry. "Having well-defined roles and a clear value is important in leadership." The episode concludes with a discussion on Summit Therapeutics' recent positive press releases and Jack's social media presence.

📗 Takeaways:

🤝Collaborations with pharma can be instrumental in making the leap from clinical practice to the pharmaceutical industry.

💹Transitioning from clinical practice to pharma requires a willingness to adapt to new priorities and challenges.

🕴Leadership in the pharmaceutical industry requires well-defined roles, clear value, and a culture of open communication and dissent.

💊The pharma industry faces challenges such as evolving regulatory approvals, acceptance of data from different regions, and incorporating patient perspectives.

🐟Working in a small pharma company offers agility, involvement in various processes, and the opportunity to make a significant impact.

👐Stay open to new perspectives and be willing to modify your opinions based on new information.

🩺Adapt to the evolving regulatory landscape and consider the challenges of generalizing data from different regions.

🏥Recognize the changing role of patients in decision-making and incorporate their perspectives and priorities.

💉Embrace the opportunities for growth and learning in a small company environment.

💊Be bold, clarify your goals, and actively pursue your desired path. 

Watch on YouTube

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Article
Accelerated drug approvals in oncology: Pros and cons
OVN Avatar Thakur, Sayanta & Lahiry, Sandeep

Accelerated drug approvals in oncology: Pros and cons

Article
Real-World Evidence in Oncology: Opportunities and Limitations
OVN Avatar Massimo Di Maio, Francesco Perrone, Pierfranco Conte

Real-World Evidence in Oncology: Opportunities and Limitations

Podcast
Patient Education for Next-Generation Sequencing to Guide Cancer Therapy
OVN Avatar The Oncology Nursing Podcast

Patient Education for Next-Generation Sequencing to Guide Cancer Therapy

Article
Pediatric Oncology Clinical Trials and Collaborative Research in Africa: Current Landscape and Future Perspectives
OVN Avatar Jaques van Heerden, MD, Mohamed Zaghloul, MD, Anouk Neven, MSc, Teresa de Rojas, MD, PhD, Jennifer Geel, MD, Catherine Patte, MD, Joyce Balagadde-Kambugu, MD, Peter Hesseling, MD, Francine Tchintseme, MD, Eric Bouffet, MD, and Laila Hessissen, MD

Pediatric Oncology Clinical Trials and Collaborative Research in Africa: Current Landscape and Future Perspectives

Article
Characterizing Exposure–Response Relationship for Therapeutic Monoclonal Antibodies in Immuno-Oncology and Beyond: Challenges, Perspectives, and Prospects
OVN Avatar Haiqing Isaac Dai, Yulia Vugmeyster, Naveen Mangal

Characterizing Exposure–Response Relationship for Therapeutic Monoclonal Antibodies in Immuno-Oncology and Beyond: Challenges, Perspectives, and Prospects

Article
Value assessment of oncology drugs using a weighted criterion-based approach
OVN Avatar Doreen A. Ezeife MD, Francois Dionne PhD, Aline Fusco Fares MD, Ellen Laura Rose Cusano MD, Rouhi Fazelzad BSc, MISt, Wenzie Ng BSc, MPharm, RPh, Don Husereau BSc Pharm, MSc, Farzad Ali BPharm, MSc, Christina Sit MSc, Barry Stein B.Com BCL, LLB, Jennifer

Value assessment of oncology drugs using a weighted criterion-based approach

Explore OVN